Multidisciplinary approach of colorectal cancer liver metastases

Table 2 Conversion rates in colorectal cancer liver metastases after perioperative chemotherapy

Trial name	Chemotherapy type	Control	n	KRAS status	Overall response	Conversion to resection	R0 resection
BEAT[61]	FOLFOX/XELOX/FOLFIRI or fluoropyrimidines + bevacizumab	No	1914	Not selected	NA	11.80%	NA
First BEAT[62]	FOLFOX/XELOX + bevacizumab	Placebo	1914	Not selected	38%	11.80%	6.3% vs 4.9%
OPUS[70]	FOLFOX + cetuximab	FOLFOX	233	Wilde type	61% vs 37%	9%	4.7% vs 2.4%
POCHER[72]	Chr IFLO + cetuximab	No	43	Wild type	79%	60%	25.70%
PRIME[77]	FOLFOX + panitumumab	FOLFOX	591	Wild type	57% vs 48%	31% vs 22%	29% vs 17%
CELIM[11]	FOLFOX6 + cetuximab	FOLFIRI + cetuximab	106	Wild type	68% vs 57%	43%	38% vs 30%
BOXER[63]	CAPOX + bevacizumab	No	47	Not selected	78%	40%	NA
Loupakis et al[55]	FOLFOXIRI + bevacizumab	FOLFIRI + bevacizumab	508	Not selected	65% vs 53%	15% vs 12%	NA
Ye et al[73]	FOLFIRI + cetuximab	FOLFOX + cetuximab	177	Wild type	57% vs 29%	26% vs 7%	NA
CRYSTAL[71]	FOLFIRI + cetuximab	FOLFIRI	599	Wilde type	47% vs 39%	16%	4.8% vs 1.7%
OLIVIA[79]	FOLFOXIRI + bevacizumab	FOLFOX + bevacizumab	80	Not selected	81% vs 62%	61% vs 49%	49% vs 23%

CAPOX, XELOX: Capecitabine-oxaliplatin; NA: Not available; Chr IFLO: Chronomodulated irinotecan, 5-fluorouracil, leucovorin, and oxalipaltin; FOLFIRI: 5-fluorouracil, leucovorin and irinotecan; FOLFOX: 5-fluorouracil, leucovorin, and oxalipaltin; FOLFOXIRI: 5-fluorouracil, leucovorin, oxalipaltin and irinotecan.